See what CanVECTOR members are publishing to advance the field of venous thromboembolism
Publications since 2016 that are linked to venous thromboembolism and/or anticoagulant therapy

Publications for Jeffrey Weitz

Updated daily

Back to Member List

#	PubMedId	Deleted	Publication
	39283934	0	Weitz JI. Arterial Thrombosis: Present and Future. Circulation. 2024 Sep 17;150(12):905-907. doi: 10.1161/CIRCULATIONAHA.124.070541. Epub 2024 Sep 16.
	39214801	0	Jain SS, Mahaffey KW, Pieper KS, et al. Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design. Am Heart J. 2024 Aug 27:S0002-8703(24)00206-0. doi: 10.1016/j.ahj.2024.08.011.
	39029742	0	Levy JH, Shaw JR, Castellucci LA, et al. Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2024 Jul 17:S1538-7836(24)00426-4. doi: 10.1016/j.jtha.2024.07.009.
	38752349	0	Malik RA, Zhou J, Fredenburgh JC, et al. Histidine-Rich Glycoprotein Modulates the Toxic Effects of High-Dose Polyphosphate in Mice. Arterioscler Thromb Vasc Biol. 2024 May 16. doi: 10.1161/ATVBAHA.124.320899.
	38657032	0	Wendelboe A, Weitz JI. Global Health Burden of Venous Thromboembolism. Arterioscler Thromb Vasc Biol. 2024 May;44(5):1007-1011. doi: 10.1161/ATVBAHA.124.320151. Epub 2024 Apr 24.
	38381695	0	Goodman SG, Roy D, Pollack CV Jr, et al. Current Gaps in the Provision of Safe and Effective Anticoagulation in Atrial Fibrillation and the Potential for Factor XI-Directed Therapeutics. Crit Pathw Cardiol. 2024 Feb 21. doi: 10.1097/HPC.0000000000000351.
	38365952	0	Weitz JI, Tanko LB, Floege J, et al. Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial. Nat Med. 2024 Feb;30(2):435-442. doi: 10.1038/s41591-023-02794-7. Epub 2024 Feb 16.
	38316416	0	Harenberg J, Gosselin RC, Cuker A, et al. Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper. Thromb Haemost. 2024 Aug;124(8):770-777. doi: 10.1055/a-2261-1811. Epub 2024 Feb 5.
	38233019	0	Bejjani A, Khairani CD, Assi A, et al. When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review. J Am Coll Cardiol. 2024 Jan 23;83(3):444-465. doi: 10.1016/j.jacc.2023.10.038.
	37751849	0	Chessum JE, Shaya SA, Rajab D, et al. Thrombin-activatable fibrinolysis inhibitor and sex modulate thrombus stability and pulmonary embolism burden in a murine model. J Thromb Haemost. 2023 Sep 24:S1538-7836(23)00718-3. doi: 10.1016/j.jtha.2023.09.016.
	37675613	0	Field TS, Dizonno V, Almekhlafi MA, et al. Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis. Stroke. 2023 Sep 7. doi: 10.1161/STROKEAHA.123.044113.
	37650326	0	Chan NC, Weitz JI. New Therapeutic Targets for the Prevention and Treatment of Venous Thromboembolism With a Focus on Factor XI Inhibitors. Arterioscler Thromb Vasc Biol. 2023 Aug 31. doi: 10.1161/ATVBAHA.123.318781.
	37429508	0	Eikelboom JW, Weitz JI. Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials. J Thromb Haemost. 2023 Nov;21(11):3067-3071. doi: 10.1016/j.jtha.2023.06.036. Epub 2023 Jul 8.
	37171998	0	Wang TF, Khorana AA, Agnelli G, et al. Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction. Oncologist. 2023 May 12:oyad116. doi: 10.1093/oncolo/oyad116.
	37116752	0	Fredenburgh JC, Weitz JI. News at XI: Moving Beyond Factor Xa Inhibitors. J Thromb Haemost. 2023 Apr 26:S1538-7836(23)00343-4. doi: 10.1016/j.jtha.2023.04.021.
	37042966	0	Malik R, Liao P, Zhou J, et al. Histidine-rich glycoprotein attenuates catheter thrombosis. Blood Adv. 2023 Apr 12:bloodadvances.2022009236. doi: 10.1182/bloodadvances.2022009236.
	36988142	0	van Es N, De Caterina R, Weitz JI. Reversal agents for current and forthcoming direct oral anticoagulants. Eur Heart J. 2023 May 21;44(20):1795-1806. doi: 10.1093/eurheartj/ehad123.
	36796485	0	Barnes GD, Ageno W, Castellucci LA, et al. Recommendation on the Nomenclature for Anticoagulants: Updated Communication from the ISTH SSC Subcommittee on the Control of Anticoagulation. J Thromb Haemost. 2023 Feb 14:S1538-7836(23)00149-6. doi: 10.1016/j.jtha.2023.02.008.
	36709763	0	Eikelboom JW, Weitz JI. Direct Oral Anticoagulants in the Very Elderly. Thromb Haemost. 2023 Apr;123(4):377-379. doi: 10.1055/a-2021-8910. Epub 2023 Jan 29.
	36695400	0	Yin R, Patel V, Malik RA, et al. Allosteric modulation of exosite 1 attenuates polyphosphate-catalyzed activation of factor XI by thrombin. J Thromb Haemost. 2023 Jan;21(1):83-93. doi: 10.1016/j.jtha.2022.10.001. Epub 2022 Dec 22.
	36695399	0	Guan Z, Wang R, Hussain RH, et al. Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro. J Thromb Haemost. 2023 Jan;21(1):76-82. doi: 10.1016/j.jtha.2022.10.020. Epub 2022 Dec 22.
	36565677	0	Turpie AGG, Farjat AE, Haas S, et al. 36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE. Thromb Res. 2022 Nov 25;222:31-39. doi: 10.1016/j.thromres.2022.11.016.
	36534732	0	Weitz JI, Eikelboom JW. What Is the Future of Factor XI Inhibitors? Circulation. 2022 Dec 20;146(25):1899-1902. doi: 10.1161/CIRCULATIONAHA.122.061132. Epub 2022 Dec 19.
	36452204	0	Haas S, Farjat AE, Pieper K, et al. On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease. TH Open. 2022 Nov 3;6(4):e354-e364. doi: 10.1055/s-0042-1757744. eCollection 2022 Oct.
	36413608	0	Afonso E, Bayat F, Ladouceur L, et al. Highly Stable Hierarchically Structured All-Polymeric Lubricant-Infused Films Prevent Thrombosis and Repel Multidrug-Resistant Pathogens. ACS Appl Mater Interfaces. 2022 Nov 22. doi: 10.1021/acsami.2c17309.
	36323490	0	Weitz JI, Szekanecz Z, Charles-Schoeman C, et al. Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors. RMD Open. 2022 Nov;8(2). pii: rmdopen-2022-002571. doi: 10.1136/rmdopen-2022-002571.
	36205248	0	Raskob GE, Ageno W, Albers G, et al. Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness. J Am Heart Assoc. 2022 Oct 7:e026229. doi: 10.1161/JAHA.122.026229.
	36121587	0	Eikelboom R, Whitlock RP, Sibilio S, et al. Direct Oral Anticoagulation Versus Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves: a Retrospective, Real-World Cohort Study. Cardiovasc Drugs Ther. 2022 Sep 19. pii: 10.1007/s10557-022-07381-5. doi: 10.1007/s10557-022-07381-5.
	36046208	0	Spyropoulos AC, Goldin M, Ageno W, et al. Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial. TH Open. 2022 Jul 11;6(3):e177-e183. doi: 10.1055/s-0042-1750379. eCollection 2022 Jul.
	35648414	0	Bikdeli B, Zahedi Tajrishi F, Sadeghipour P, et al. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review. JAMA Cardiol. 2022 Jun 1. pii: 2793119. doi: 10.1001/jamacardio.2022.1292.
	35389229	0	Spyropoulos AC, Raskob GE, Cohen AT, et al. Association of Bleeding Severity with Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. Circulation. 2022 Apr 7. doi: 10.1161/CIRCULATIONAHA.121.057847.
	35224860	0	Khan S, Jarad NA, Ladouceur L, et al. Transparent and Highly Flexible Hierarchically Structured Polydimethylsiloxane Surfaces Suppress Bacterial Attachment and Thrombosis Under Static and Dynamic Conditions. Small. 2022 Feb 28:e2108112. doi: 10.1002/smll.202108112.
	35189662	0	Goldin M, Koulas I, Weitz JI, et al. State-of-the-art-mini review: Dual pathway inhibition to reduce arterial and venous thromboembolism. Thromb Haemost. 2022 Feb 21. doi: 10.1055/a-1778-1083.
	34967109	0	Truong TK, Malik RA, Yao X, et al. Identification of the histidine-rich glycoprotein domains responsible for contact pathway inhibition. J Thromb Haemost. 2021 Dec 30. doi: 10.1111/jth.15631.
	34962979	0	Bonaca MP, Antman EM, Cunningham JW, et al. Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48. Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29;8(7):695-706. doi: 10.1093/ehjcvp/pvab089.
	34920389	0	Angchaisuksiri P, Goto S, Farjat AE, et al. Corrigendum to "Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE" [Thromb. Res. 2021 May;201:63-72]. Thromb Res. 2021 Dec 15;209:105. doi: 10.1016/j.thromres.2021.11.022.
	34863582	0	Bounameaux H, Haas S, Farjat AE, et al. Corrigendum to "Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE" [Thromb. Res. 2020 Jul; 191:103-112]. Thromb Res. 2021 Dec 1. pii: S0049-3848(21)00545-4. doi: 10.1016/j.thromres.2021.11.023.
	34780683	0	Weitz JI, Strony J, Ageno W, et al. Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med. 2021 Nov 15. doi: 10.1056/NEJMoa2113194.
	34753191	0	Khan F, Rahman A, Tritschler T, et al. Long-term risk of major bleeding after discontinuing anticoagulation for unprovoked venous thromboembolism: a systematic review and meta-analysis. Thromb Haemost. 2021 Nov 9. doi: 10.1055/a-1690-8728.
	34731547	0	Weitz JI, Raskob GE, Yi BA. Abelacimab for Prevention of Venous Thromboembolism. Reply. N Engl J Med. 2021 Nov 4;385(19):1822-1823. doi: 10.1056/NEJMc2114895.
	34724403	0	Chan NC, Weitz JI. In pregnant women with suspected VTE and low/intermediate or unlikely pretest probability, D-dimer rules out VTE at 3 mo. Ann Intern Med. 2021 Nov 2. doi: 10.7326/ACPJ202111160-130.
	34714962	0	Cohen O, Ageno W, Farjat AE, et al. Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD-VTE. J Thromb Haemost. 2021 Oct 29. doi: 10.1111/jth.15574.
	34617959	0	Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Intern Med. 2021 Oct 7. pii: 2785004. doi: 10.1001/jamainternmed.2021.6203.
	34600964	0	Eikelboom J, Floege J, Thadhani R, et al. Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. Kidney Int. 2021 Sep 30. pii: S0085-2538(21)00870-X. doi: 10.1016/j.kint.2021.08.028.
	34516270	0	Khan F, Tritschler T, Kimpton M, et al. Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis. Ann Intern Med. 2021 Oct;174(10):1420-1429. doi: 10.7326/M21-1094. Epub 2021 Sep 14.
	34487616	0	Weitz JI, Farjat AE, Ageno W, et al. Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE. J Thromb Haemost. 2021 Sep 6. doi: 10.1111/jth.15520.
	34474475	0	Malik RA, Zhou J, Fredenburgh JC, et al. Polyphosphate-induced thrombosis in mice is factor XII dependent and is attenuated by histidine-rich glycoprotein. Blood Adv. 2021 Sep 28;5(18):3540-3551. doi: 10.1182/bloodadvances.2021004567.
	34455706	0	Bosch FTM, Mulder FI, Huisman MV, et al. Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. J Thromb Haemost. 2021 Aug 29. doi: 10.1111/jth.15516.
	34379859	0	Khan F, Tritschler T, Kimpton M, et al. Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. J Thromb Haemost. 2021 Nov;19(11):2801-2813. doi: 10.1111/jth.15491. Epub 2021 Aug 22.
	34353538	0	Hsu C, Hutt E, Bloomfield DM, et al. Factor XI Inhibition to Uncouple Thrombosis From Hemostasis: JACC Review Topic of the Week. J Am Coll Cardiol. 2021 Aug 10;78(6):625-631. doi: 10.1016/j.jacc.2021.06.010.
	34314574	0	Ageno W, Lopes RD, Goldin M, et al. Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. J Thromb Haemost. 2021 Nov;19(11):2772-2780. doi: 10.1111/jth.15477. Epub 2021 Aug 17.
	34297496	0	Verhamme P, Yi BA, Segers A, et al. Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med. 2021 Aug 12;385(7):609-617. doi: 10.1056/NEJMoa2105872. Epub 2021 Jul 19.
	34176221	0	Weitz JI, Peyvandi F. International Society on Thrombosis and Haemostasis: Present and future. J Thromb Haemost. 2021 Jul;19(7):1599-1601. doi: 10.1111/jth.15325.
	34086880	0	Lorentz CU, Tucker EI, Verbout NG, et al. The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood. 2021 Dec 2;138(22):2173-2184. doi: 10.1182/blood.2021011725.
	34023735	0	Goto S, Turpie AGG, Farjat AE, et al. The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE. Thromb Res. 2021 Jul;203:155-162. doi: 10.1016/j.thromres.2021.05.007. Epub 2021 May 15.
	33860518	0	Fredenburgh JC, Weitz JI. Factor XI as a Target for New Anticoagulants. Hamostaseologie. 2021 Apr;41(2):104-110. doi: 10.1055/a-1384-3715. Epub 2021 Apr 15.
	33826233	0	Juneja GK, Castelo M, Yeh CH, et al. Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID-19: A single-center prospective longitudinal study. J Thromb Haemost. 2021 Jun;19(6):1546-1557. doi: 10.1111/jth.15327. Epub 2021 May 1.
	33823560	0	Goldin M, Giannis D, Diab W, et al. Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial. Thromb Haemost. 2021 Apr 6. doi: 10.1055/a-1475-2351.
	33741176	0	Talasaz AH, Sadeghipour P, Kakavand H, et al. Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021 Apr 20;77(15):1903-1921. doi: 10.1016/j.jacc.2021.02.035. Epub 2021 Mar 16.
	33733032	0	Ageno W, Farjat A, Haas S, et al. Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD-VTE. Res Pract Thromb Haemost. 2021 Feb 20;5(2):326-341. doi: 10.1002/rth2.12482. eCollection 2021 Feb.
	33733030	0	Boonyawat K, Lensing AWA, Prins MH, et al. Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high- and low-dose rivaroxaban with aspirin. Res Pract Thromb Haemost. 2021 Feb 17;5(2):308-313. doi: 10.1002/rth2.12474. eCollection 2021 Feb.
	33652328	0	Angchaisuksiri P, Goto S, Farjat AE, et al. Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE. Thromb Res. 2021 May;201:63-72. doi: 10.1016/j.thromres.2021.02.024. Epub 2021 Feb 24.
	33586478	0	Raskob GE, Spyropoulos AC, Cohen AT, et al. Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients. J Am Heart Assoc. 2021 Feb;10(5):e019459. doi: 10.1161/JAHA.120.019459. Epub 2021 Feb 15.
	33532693	0	Jerjes-Sanchez C, Rodriguez D, Farjat AE, et al. Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. TH Open. 2021 Jan 27;5(1):e24-e34. doi: 10.1055/s-0040-1722611. eCollection 2021 Jan.
	33470781	0	Kasapgil E, Badv M, Cantu CA, et al. Polysiloxane Nanofilaments Infused with Silicone Oil Prevent Bacterial Adhesion and Suppress Thrombosis on Intranasal Splints. ACS Biomater Sci Eng. 2021 Feb 8;7(2):541-552. doi: 10.1021/acsbiomaterials.0c01487. Epub 2021 Jan 20.
	33417801	0	Badv M, Alonso-Cantu C, Shakeri A, et al. Biofunctional Lubricant-Infused Vascular Grafts Functionalized with Silanized Bio-Inks Suppress Thrombin Generation and Promote Endothelialization. ACS Biomater Sci Eng. 2019 Dec 9;5(12):6485-6496. doi: 10.1021/acsbiomaterials.9b01062. Epub 2019 Nov 8.
	33376944	0	Weitz JI, Prandoni P, Verhamme P. Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required? TH Open. 2020 Dec 23;4(4):e446-e456. doi: 10.1055/s-0040-1721735. eCollection 2020 Oct.
	33254037	0	Riess H, Verhamme P, Weitz JI, et al. Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management. Crit Rev Oncol Hematol. 2021 Jan;157:103125. doi: 10.1016/j.critrevonc.2020.103125. Epub 2020 Oct 20.
	33112399	0	Goto S, Haas S, Ageno W, et al. Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease. JAMA Netw Open. 2020 Oct 1;3(10):e2022886. doi: 10.1001/jamanetworkopen.2020.22886.
	33082930	0	Chan NC, Weitz JI. Recent advances in understanding, diagnosing and treating venous thrombosis. F1000Res. 2020 Oct 6;9. doi: 10.12688/f1000research.27115.1. eCollection 2020.
	33047462	0	Fredenburgh JC, Weitz JI. New anticoagulants: Moving beyond the direct oral anticoagulants. J Thromb Haemost. 2021 Jan;19(1):20-29. doi: 10.1111/jth.15126. Epub 2020 Nov 3.
	32702124	0	Chan NC, Weitz JI. COVID-19 coagulopathy, thrombosis, and bleeding. Blood. 2020 Jul 23;136(4):381-383. doi: 10.1182/blood.2020007335.
	32658609	0	Spyropoulos AC, Weitz JI. Hospitalized COVID-19 Patients and Venous Thromboembolism: A Perfect Storm. Circulation. 2020 Jul 14;142(2):129-132. doi: 10.1161/CIRCULATIONAHA.120.048020. Epub 2020 Jul 13.
	32594508	0	Weitz JI, Angiolillo DJ, Geisler T, et al. Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence. Thromb Haemost. 2020 Aug;120(8):1147-1158. doi: 10.1055/s-0040-1713376. Epub 2020 Jun 28.
	32586587	0	Spyropoulos AC, Ageno W, Albers GW, et al. Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. J Am Coll Cardiol. 2020 Jun 30;75(25):3140-3147. doi: 10.1016/j.jacc.2020.04.071.
	32583306	0	Weitz JI, Haas S, Ageno W, et al. Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. J Thromb Thrombolysis. 2020 Aug;50(2):267-277. doi: 10.1007/s11239-020-02180-x.
	32506822	0	Ni R, Neves MAD, Wu C, et al. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin-dependent plasmin generation on thrombin-activated platelets. J Thromb Haemost. 2020 Sep;18(9):2364-2376. doi: 10.1111/jth.14950.
	32473596	0	Bikdeli B, Madhavan MV, Gupta A, et al. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thromb Haemost. 2020 Jul;120(7):1004-1024. doi: 10.1055/s-0040-1713152. Epub 2020 May 30.
	32422442	0	Bounameaux H, Haas S, Farjat AE, et al. Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. Thromb Res. 2020 Jul;191:103-112. doi: 10.1016/j.thromres.2020.04.036. Epub 2020 Apr 28.
	32396939	0	Mulder FI, Bosch FTM, Young AM, et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood. 2020 Sep 17;136(12):1433-1441. doi: 10.1182/blood.2020005819.
	32369855	0	Giustozzi M, Curcio A, Weijs B, et al. Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer. Thromb Haemost. 2020 May;120(5):847-856. doi: 10.1055/s-0040-1709527. Epub 2020 May 5.
	32323192	0	Zhang L, Yan X, Fox KAA, et al. Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. J Thromb Thrombolysis. 2020 Jul;50(1):20-29. doi: 10.1007/s11239-020-02077-9.
	32323191	0	Solms A, Willmann S, Reinecke I, et al. Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2020 Jul;50(1):1-11. doi: 10.1007/s11239-020-02073-z.
	32323190	0	Reinecke I, Solms A, Willmann S, et al. Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism. J Thromb Thrombolysis. 2020 Jul;50(1):12-19. doi: 10.1007/s11239-020-02078-8.
	32311448	0	Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973. doi: 10.1016/j.jacc.2020.04.031. Epub 2020 Apr 17.
	32202042	0	Valeriani E, Porreca E, Weitz JI, et al. Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and meta-analysis. J Thromb Haemost. 2020 Jul;18(7):1661-1671. doi: 10.1111/jth.14807. Epub 2020 Apr 16.
	32132678	0	Mackman N, Bergmeier W, Stouffer GA, et al. Therapeutic strategies for thrombosis: new targets and approaches. Nat Rev Drug Discov. 2020 May;19(5):333-352. doi: 10.1038/s41573-020-0061-0. Epub 2020 Mar 4.
	31975354	0	Weitz JI, Raskob GE, Spyropoulos AC, et al. Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. Thromb Haemost. 2020 Mar;120(3):515-524. doi: 10.1055/s-0039-1701009. Epub 2020 Jan 23.
	31953535	0	Capodanno D, Bhatt DL, Eikelboom JW, et al. Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nat Rev Cardiol. 2020 Apr;17(4):242-257. doi: 10.1038/s41569-019-0314-y. Epub 2020 Jan 17.
	31935028	0	Weitz JI, Bauersachs R, Becker B, et al. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA. 2020 Jan 14;323(2):130-139. doi: 10.1001/jama.2019.20687.
	31917385	0	Weitz JI, Chan NC. Novel antithrombotic strategies for treatment of venous thromboembolism. Blood. 2020 Jan 30;135(5):351-359. doi: 10.1182/blood.2019000919.
	31877292	0	Jaffer IH, Fredenburgh JC, Stafford A, et al. Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve-Induced Thrombin Generation. Ann Thorac Surg. 2020 Aug;110(2):582-590. doi: 10.1016/j.athoracsur.2019.10.091. Epub 2019 Dec 24.
	31858522	0	Schindewolf M, Weitz JI. Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment. Thromb Haemost. 2020 Jan;120(1):14-26. doi: 10.1055/s-0039-3400302. Epub 2019 Dec 13.
	31727694	0	Mulder FI, Di Nisio M, Ay C, et al. Clinical implications of incidental venous thromboembolism in cancer patients. Eur Respir J. 2020 Feb 6;55(2). pii: 13993003.01697-2019. doi: 10.1183/13993003.01697-2019. Print 2020 Feb.
	31648712	0	Weitz JI, Chan NC. Are Ticks the Answer to Medical Device-Associated Clotting? J Am Coll Cardiol. 2019 Oct 29;74(17):2190-2192. doi: 10.1016/j.jacc.2019.08.1027.
	31599808	0	Levy JH, van Ryn J, Sellke FW, et al. Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study. Ann Surg. 2021 Sep 1;274(3):e204-e211. doi: 10.1097/SLA.0000000000003638.
	31582135	0	Eikelboom JW, van Ryn J, Reilly P, et al. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. J Am Coll Cardiol. 2019 Oct 8;74(14):1760-1768. doi: 10.1016/j.jacc.2019.07.070.
	31529590	0	Weitz JI, Segers A, Raskob G, et al. Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis. J Thromb Haemost. 2019 Dec;17(12):2081-2088. doi: 10.1111/jth.14639. Epub 2019 Oct 13.
	31370075	0	Schellong SM, Goldhaber SZ, Weitz JI, et al. Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry. Thromb Haemost. 2019 Oct;119(10):1675-1685. doi: 10.1055/s-0039-1693461. Epub 2019 Aug 1.
	31364490	0	Zhang L, Yan X, Nandy P, et al. Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome. Ther Adv Cardiovasc Dis. 2019 Jan-Dec;13:1753944719863641. doi: 10.1177/1753944719863641.
	31340984	0	Khan F, Rahman A, Carrier M, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ. 2019 Jul 24;366:l4363. doi: 10.1136/bmj.l4363.
	31271705	0	Di Nisio M, van Es N, Carrier M, et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost. 2019 Nov;17(11):1866-1874. doi: 10.1111/jth.14561. Epub 2019 Jul 25.
	31249922	0	Brekelmans MPA, Buller HR, Mercuri MF, et al. Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. TH Open. 2018 Jan 8;2(1):e1-e7. doi: 10.1055/s-0037-1615251. eCollection 2018 Jan.
	31226480	0	Jaffer IH, Weitz JI. The blood compatibility challenge. Part 1: Blood-contacting medical devices: The scope of the problem. Acta Biomater. 2019 Aug;94:2-10. doi: 10.1016/j.actbio.2019.06.021. Epub 2019 Jun 18.
	31220403	0	Haas S, Ageno W, Weitz JI, et al. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. J Thromb Haemost. 2019 Oct;17(10):1694-1706. doi: 10.1111/jth.14548. Epub 2019 Jul 23.
	31183844	0	Ageno W, Haas S, Weitz JI, et al. Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. Thromb Haemost. 2019 Aug;119(8):1365-1372. doi: 10.1055/s-0039-1688828. Epub 2019 Jun 10.
	31034291	0	Gurbel PA, Fox KAA, Tantry US, et al. Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. Circulation. 2019 Apr 30;139(18):2170-2185. doi: 10.1161/CIRCULATIONAHA.118.033580.
	31005064	0	Shaya SA, Gani DM, Weitz JI, et al. Factor XIII Prevents Pulmonary Emboli in Mice by Stabilizing Deep Vein Thrombi. Thromb Haemost. 2019 Jun;119(6):992-999. doi: 10.1055/s-0039-1685141. Epub 2019 Apr 20.
	30923107	0	Weitz JI, Chan NC. MAA868 locks factor XIa in a zymogen-like state. Blood. 2019 Mar 28;133(13):1393-1394. doi: 10.1182/blood-2019-02-900480.
	30919384	0	Field TS, Weijs B, Curcio A, et al. Incident Atrial Fibrillation, Dementia and the Role of Anticoagulation: A Population-Based Cohort Study. Thromb Haemost. 2019 Jun;119(6):981-991. doi: 10.1055/s-0039-1683429. Epub 2019 Mar 27.
	30917049	0	Chan NC, Weitz JI. AB023, A Novel Antibody That Binds Factor XI and Blocks Its Activation by Factor XIIa. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):533-535. doi: 10.1161/ATVBAHA.119.312459.
	30846497	0	Cate VT, Lensing AWA, Weitz JI, et al. Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study. Haematologica. 2019 Oct;104(10):e474-e477. doi: 10.3324/haematol.2018.209924. Epub 2019 Mar 7.
	30808045	0	Weitz JI, Chan NC. Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials. Thromb Haemost. 2019 May;119(5):689-694. doi: 10.1055/s-0039-1679906. Epub 2019 Feb 26.
	30779598	0	Chan NC, Weitz JI. Rivaroxaban for prevention and treatment of venous thromboembolism. Future Cardiol. 2019 Mar;15(2):63-77. doi: 10.2217/fca-2018-0076. Epub 2019 Feb 19.
	30702997	0	Coppens M, Weitz JI, Eikelboom JWA. Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. Circ Res. 2019 Feb;124(3):416-425. doi: 10.1161/CIRCRESAHA.118.313141.
	30702992	0	Weitz JI, Fazio S. Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis. Circ Res. 2019 Feb;124(3):351-353. doi: 10.1161/CIRCRESAHA.118.314576.
	30702990	0	Chan NC, Weitz JI. Antithrombotic Agents. Circ Res. 2019 Feb;124(3):426-436. doi: 10.1161/CIRCRESAHA.118.313155.
	30650446	0	Cohen AT, Agnelli G, Buller HR, et al. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. Thromb Haemost. 2019 Mar;119(3):461-466. doi: 10.1055/s-0038-1676983. Epub 2019 Jan 16.
	30597497	0	De Caterina R, Ageno W, Agnelli G, et al. The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thromb Haemost. 2019 Jan;119(1):14-38. doi: 10.1055/s-0038-1675816. Epub 2018 Dec 31.
	30593086	0	Ageno W, Haas S, Weitz JI, et al. Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. Thromb Haemost. 2019 Feb;119(2):319-327. doi: 10.1055/s-0038-1676611. Epub 2018 Dec 28.
	30580558	0	Weitz JI, Chan NC. Advances in Antithrombotic Therapy. Arterioscler Thromb Vasc Biol. 2019 Jan;39(1):7-12. doi: 10.1161/ATVBAHA.118.310960.
	30482761	0	Willmann S, Zhang L, Mayer H, et al. Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients. Blood Adv. 2018 Nov 27;2(22):3193-3195. doi: 10.1182/bloodadvances.2018027078.
	30354213	0	Ni R, Vaezzadeh N, Zhou J, et al. Effect of Different Doses of Acetylsalicylic Acid on the Antithrombotic Activity of Clopidogrel in a Mouse Arterial Thrombosis Model. Arterioscler Thromb Vasc Biol. 2018 Oct;38(10):2338-2344. doi: 10.1161/ATVBAHA.118.311404.
	30352507	0	Badv M, Imani SM, Weitz JI, et al. Lubricant-Infused Surfaces with Built-In Functional Biomolecules Exhibit Simultaneous Repellency and Tunable Cell Adhesion. ACS Nano. 2018 Nov 27;12(11):10890-10902. doi: 10.1021/acsnano.8b03938. Epub 2018 Oct 24.
	30145946	0	Spyropoulos AC, Ageno W, Albers GW, et al. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 Sep 20;379(12):1118-1127. doi: 10.1056/NEJMoa1805090. Epub 2018 Aug 26.
	30121419	0	Ten Cate H, Lensing AWA, Weitz JI, et al. The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. Thromb Res. 2018 Oct;170:75-83. doi: 10.1016/j.thromres.2018.08.008. Epub 2018 Aug 15.
	30093297	0	Weitz JI, Earl KM, Leblanc K, et al. Establishing Therapeutic Equivalence of Complex Pharmaceuticals: The Case of Dabigatran. Can J Cardiol. 2018 Sep;34(9):1116-1119. doi: 10.1016/j.cjca.2018.05.023. Epub 2018 Jun 5.
	30064683	0	Prandoni P, Lensing AWA, Prins MH, et al. Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. Thromb Res. 2018 Aug;168:121-129. doi: 10.1016/j.thromres.2018.06.009. Epub 2018 Jul 10.
	30060256	0	Kraaijpoel N, Di Nisio M, Mulder FI, et al. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thromb Haemost. 2018 Aug;118(8):1439-1449. doi: 10.1055/s-0038-1667001. Epub 2018 Jul 30.
	30046706	0	Wendelboe AM, Raskob GE, Angchaisuksiri P, et al. Global public awareness about atrial fibrillation. Res Pract Thromb Haemost. 2017 Oct 25;2(1):49-57. doi: 10.1002/rth2.12051. eCollection 2018 Jan.
	30046668	0	Pabinger I, Reiser T, Weitz JI. Research and Practice in Thrombosis and Haemostasis - a new ISTH publishing platform for the global thrombosis and hemostasis community. Res Pract Thromb Haemost. 2017 May 30;1(1):6-8. doi: 10.1002/rth2.12005. eCollection 2017 Jul.
	30042148	0	Chan NC, Weitz JI. Antiplatelet therapy in the management of atherothrombosis: recent clinical advances. Blood Adv. 2018 Jul 24;2(14):1806. doi: 10.1182/bloodadvances.2018005074.
	29967197	0	Yin OQP, Antman EM, Braunwald E, et al. Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. Circulation. 2018 Oct 30;138(18):1963-1973. doi: 10.1161/CIRCULATIONAHA.118.033933.
	29790365	0	Andrade JG, Meseguer E, Didier R, et al. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with bioprosthetic valves. Expert Rev Cardiovasc Ther. 2018 May 23:1-6. doi: 10.1080/14779072.2018.1475229.
	29766772	0	Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med. 2018 Jun 7;378(23):2191-2201. doi: 10.1056/NEJMoa1802686. Epub 2018 May 16.
	29748353	0	Aisenberg J, Chatterjee-Murphy P, Friedman Flack K, et al. Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction). Circ Cardiovasc Qual Outcomes. 2018 May;11(5):e003998. doi: 10.1161/CIRCOUTCOMES.117.003998.
	29723874	0	Douketis JD, Murphy SA, Antman EM, et al. Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. Thromb Haemost. 2018 Jun;118(6):1001-1008. doi: 10.1055/s-0038-1645856. Epub 2018 May 3.
	29632234	0	Prins MH, Lensing AWA, Prandoni P, et al. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Adv. 2018 Apr 10;2(7):788-796. doi: 10.1182/bloodadvances.2018017160.
	29566417	0	Khorana AA, Weitz JI. Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies. Thromb Haemost. 2018 May;118(S 01):S23-S33. doi: 10.1160/TH17-09-0681. Epub 2018 Mar 22.
	29525076	0	Kasner SE, Lavados P, Sharma M, et al. Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. J Stroke Cerebrovasc Dis. 2018 Jun;27(6):1673-1682. doi: 10.1016/j.jstrokecerebrovasdis.2018.01.027. Epub 2018 Mar 7.
	29490924	0	Kearon C, Parpia S, Spencer FA, et al. Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood. 2018 May 10;131(19):2151-2160. doi: 10.1182/blood-2017-09-805689. Epub 2018 Feb 28.
	29345686	0	Levy JH, Douketis J, Weitz JI. Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol. 2018 May;15(5):273-281. doi: 10.1038/nrcardio.2017.223. Epub 2018 Jan 18.
	29269514	0	Weitz JI, Fredenburgh JC. 2017 Scientific Sessions Sol Sherry Distinguished Lecture in Thrombosis: Factor XI as a Target for New Anticoagulants. Arterioscler Thromb Vasc Biol. 2018 Feb;38(2):304-310. doi: 10.1161/ATVBAHA.117.309664. Epub 2017 Dec 21.
	29248859	0	Vanassche T, Verhamme P, Wells PS, et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. Thromb Res. 2018 Feb;162:7-14. doi: 10.1016/j.thromres.2017.12.005. Epub 2017 Dec 13.
	29231094	0	Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 Feb 15;378(7):615-624. doi: 10.1056/NEJMoa1711948. Epub 2017 Dec 12.
	29212128	0	Medina A, Raskob G, Ageno W, et al. Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2017 Dec;117(12):2406-2414. doi: 10.1160/TH17-05-0523. Epub 2017 Dec 6.
	29212109	0	Chan NC, Weitz JI. Measuring Dabigatran Levels: What Tests Are Available and What Still Needs to Be Done? Thromb Haemost. 2017 Dec;117(12):2213-2214. doi: 10.1160/TH17-10-0705. Epub 2017 Dec 6.
	29096812	0	Weitz JI, Fredenburgh JC, Eikelboom JW. A Test in Context: D-Dimer. J Am Coll Cardiol. 2017 Nov 7;70(19):2411-2420. doi: 10.1016/j.jacc.2017.09.024.
	28912558	0	Badv M, Jaffer IH, Weitz JI, et al. An omniphobic lubricant-infused coating produced by chemical vapor deposition of hydrophobic organosilanes attenuates clotting on catheter surfaces. Sci Rep. 2017 Sep 14;7(1):11639. doi: 10.1038/s41598-017-12149-1.
	28713563	0	Weitz JI, Jaffer IH, Fredenburgh JC. Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants. F1000Res. 2017 Jun 23;6:985. doi: 10.12688/f1000research.11174.1. eCollection 2017.
	28693366	0	Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med. 2017 Aug 3;377(5):431-441. doi: 10.1056/NEJMoa1707278. Epub 2017 Jul 11.
	28640323	0	Wu C, Stafford AR, Fredenburgh JC, et al. Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential. Thromb Haemost. 2017 Jul 26;117(8):1509-1517. doi: 10.1160/TH17-01-0054. Epub 2017 Jun 22.
	28636848	0	Weitz JI, Lensing AWA, Prins MH. Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017 Jun 22;376(25):2491-2492. doi: 10.1056/NEJMc1705484.
	28594426	0	Weitz JI, Harenberg J. New developments in anticoagulants: Past, present and future. Thromb Haemost. 2017 Jun 28;117(7):1283-1288. doi: 10.1160/TH16-10-0807. Epub 2017 Jun 8.
	28583286	0	Beyer-Westendorf J, Schellong SM, Gerlach H, et al. Evaluation of direct oral anticoagulants in superficial-vein thrombosis - Authors' reply. Lancet Haematol. 2017 Jun;4(6):e254-e255. doi: 10.1016/S2352-3026(17)30086-8.
	28446469	0	Chan NC, Weitz JI, Eikelboom JW. Anticoagulation for Mechanical Heart Valves: Will Oral Factor Xa Inhibitors Be Effective? Arterioscler Thromb Vasc Biol. 2017 May;37(5):743-745. doi: 10.1161/ATVBAHA.117.309223.
	28400486	0	Steiner T, Weitz JI, Veltkamp R. Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents. Stroke. 2017 May;48(5):1432-1437. doi: 10.1161/STROKEAHA.116.013343. Epub 2017 Apr 11.
	28355459	0	Eikelboom JW, Quinlan DJ, Hirsh J, et al. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review. JAMA Cardiol. 2017 May 1;2(5):566-574. doi: 10.1001/jamacardio.2017.0364.
	28336732	0	Weitz JI, Fredenburgh JC. Platelet polyphosphate: the long and the short of it. Blood. 2017 Mar 23;129(12):1574-1575. doi: 10.1182/blood-2017-01-761593.
	28316279	0	Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017 Mar 30;376(13):1211-1222. doi: 10.1056/NEJMoa1700518. Epub 2017 Mar 18.
	28286749	0	Weitz JI, Fredenburgh JC. Factors XI and XII as Targets for New Anticoagulants. Front Med (Lausanne). 2017 Feb 24;4:19. doi: 10.3389/fmed.2017.00019. eCollection 2017.
	28219692	0	Beyer-Westendorf J, Schellong SM, Gerlach H, et al. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol. 2017 Mar;4(3):e105-e113. doi: 10.1016/S2352-3026(17)30014-5. Epub 2017 Feb 16.
	28208197	0	Weitz JI. Reversal of Direct Oral Anticoagulants: Current Status and Future Directions. Semin Respir Crit Care Med. 2017 Feb;38(1):40-50. doi: 10.1055/s-0036-1597831. Epub 2017 Feb 16.
	28051778	0	Fredenburgh JC, Weitz JI. A PoTENtial Antidote: A Prohemostatic Factor Xa Variant for Reversal of Direct Oral Anticoagulants. Circ Res. 2016 Nov 11;119(11):1157-1160. doi: 10.1161/CIRCRESAHA.116.309820.
	27981865	0	Pollack CV Jr, Bernstein R, Dubiel R, et al. Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD study. J Med Econ. 2017 May;20(5):435-442. doi: 10.1080/13696998.2016.1273229. Epub 2017 Jan 17.
	27978952	0	Dangas GD, Weitz JI, Giustino G, et al. Prosthetic Heart Valve Thrombosis. J Am Coll Cardiol. 2016 Dec 20;68(24):2670-2689. doi: 10.1016/j.jacc.2016.09.958.
	27886530	0	Beyer-Westendorf J, Lensing AW, Arya R, et al. Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. Thromb Res. 2017 Jan;149:29-37. doi: 10.1016/j.thromres.2016.11.014. Epub 2016 Nov 21.
	27780803	0	Fredenburgh JC, Gross PL, Weitz JI. Emerging anticoagulant strategies. Blood. 2017 Jan 12;129(2):147-154. doi: 10.1182/blood-2016-09-692996. Epub 2016 Oct 25.
	27656711	0	Weitz JI, Haas S, Ageno W, et al. Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design. Thromb Haemost. 2016 Nov 30;116(6):1172-1179. doi: 10.1160/TH16-04-0335. Epub 2016 Sep 22.
	27592622	0	Weitz JI, Jaffer IH. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants. Pol Arch Med Wewn. 2016 Sep 5;126(9):688-696. doi: 10.20452/pamw.3547. Epub 2016 Sep 5.
	27583312	0	Bleker SM, Cohen AT, Buller HR, et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. Thromb Haemost. 2016 Nov 30;116(6):1159-1164. doi: 10.1160/TH16-02-0137. Epub 2016 Sep 1.
	27570090	0	Brekelmans MP, Ageno W, Beenen LF, et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 Sep;3(9):e437-45. doi: 10.1016/S2352-3026(16)30080-1.
	27476789	0	Raskob GE, van Es N, Segers A, et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016 Aug;3(8):e379-87. doi: 10.1016/S2352-3026(16)30057-6. Epub 2016 Jul 1.
	27440518	0	Verhamme P, Wells PS, Segers A, et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thromb Haemost. 2016 Sep 27;116(4):747-53. doi: 10.1160/TH16-03-0244. Epub 2016 Jul 21.
	27436877	0	Weitz JI, Eikelboom JW. Urgent Need to Measure Effects of Direct Oral Anticoagulants. Circulation. 2016 Jul 19;134(3):186-8. doi: 10.1161/CIRCULATIONAHA.116.022307.
	27352238	0	Eriksson BI, Mikuska Z, Feuring M, et al. An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery. Thromb Res. 2016 Aug;144:158-64. doi: 10.1016/j.thromres.2016.06.017. Epub 2016 Jun 16.
	27305147	0	Yeh CH, Stafford AR, Leslie BA, et al. Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function. PLoS One. 2016 Jun 15;11(6):e0157471. doi: 10.1371/journal.pone.0157471. eCollection 2016.
	27297852	0	Reiffel JA, Weitz JI, Reilly P, et al. NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. Am Heart J. 2016 Jul;177:74-86. doi: 10.1016/j.ahj.2016.04.010. Epub 2016 Apr 23.
	27224445	0	Peetermans M, Pollack C Jr, Reilly P, et al. Idarucizumab for dabigatran overdose. Clin Toxicol (Phila). 2016 Sep;54(8):644-6. doi: 10.1080/15563650.2016.1187737. Epub 2016 May 25.
	27207423	0	Weitz JI. Factor XI and factor XII as targets for new anticoagulants. Thromb Res. 2016 May;141 Suppl 2:S40-5. doi: 10.1016/S0049-3848(16)30363-2.
	27189130	0	Wolberg AS, Rosendaal FR, Weitz JI, et al. Venous thrombosis. Nat Rev Dis Primers. 2015 May 7;1:15006. doi: 10.1038/nrdp.2015.6.
	27173100	0	Whitlock RP, Fordyce CB, Midei MG, et al. A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial. Thromb Haemost. 2016 Aug 1;116(2):241-50. doi: 10.1160/TH15-11-0910. Epub 2016 May 12.
	27132697	0	Raskob G, Ageno W, Cohen AT, et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 May;3(5):e228-36. doi: 10.1016/S2352-3026(16)00023-5. Epub 2016 Mar 22.
	27126650	0	Chan NC, Eikelboom JW, Weitz JI. Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants. Circ Res. 2016 Apr 29;118(9):1409-24. doi: 10.1161/CIRCRESAHA.116.306925.
	27126644	0	Weitz JI, Eikelboom JW. Advances in Thrombosis and Hemostasis: An Introduction to the Compendium. Circ Res. 2016 Apr 29;118(9):1337-9. doi: 10.1161/CIRCRESAHA.116.308844.
	27126598	0	Ruff CT, Ansell JE, Becker RC, et al. North American Thrombosis Forum, AF Action Initiative Consensus Document. Am J Med. 2016 May;129(5 Suppl):S1-S29. doi: 10.1016/j.amjmed.2016.02.001.
	26952877	0	De Caterina R, Husted S, Wallentin L, et al. Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2016 Apr;115(4):685-711. doi: 10.1160/TH15-09-0703. Epub 2016 Mar 8.
	26842902	0	Raskob GE, Spyropoulos AC, Zrubek J, et al. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost. 2016 Jun 2;115(6):1240-8. doi: 10.1160/TH15-09-0756. Epub 2016 Feb 4.
	26700008	0	Eikelboom JW, Quinlan DJ, van Ryn J, et al. Idarucizumab: The Antidote for Reversal of Dabigatran. Circulation. 2015 Dec 22;132(25):2412-22. doi: 10.1161/CIRCULATIONAHA.115.019628.
	26663474	0	Levy JH, Weitz JI, Bernstein RA, et al. Letter to the Editor: Managing Dabigatran-Related Bleeding. J Intensive Care Med. 2016 Jan;31(1):70-1. doi: 10.1177/0885066614542758.
	26661288	0	Raskob GE, Gallus AS, Sanders P, et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thromb Haemost. 2016 Apr;115(4):809-16. doi: 10.1160/TH15-09-0752. Epub 2015 Dec 10.
	26494232	0	Gould TJ, Vu TT, Stafford AR, et al. Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis. Arterioscler Thromb Vasc Biol. 2015 Dec;35(12):2544-53. doi: 10.1161/ATVBAHA.115.306035. Epub 2015 Oct 22.
	26489782	0	Henderson SJ, Xia J, Wu H, et al. Zinc promotes clot stability by accelerating clot formation and modifying fibrin structure. Thromb Haemost. 2016 Mar;115(3):533-42. doi: 10.1160/TH15-06-0462. Epub 2015 Oct 22.
	26481493	0	Weitz JI, Semchuk W, Turpie AG, et al. Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014. Clin Ther. 2015 Nov 1;37(11):2506-2514.e4. doi: 10.1016/j.clinthera.2015.09.008. Epub 2015 Oct 16.
	26466666	0	Weitz JI, Eikelboom J. Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation. Thromb Haemost. 2016 Jan;115(2):257-70. doi: 10.1160/TH15-02-0181. Epub 2015 Oct 15.
	26387731	0	ten Cate-Hoek AJ, Weitz JI, Gailani D, et al. Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS). Thromb Res. 2015 Sep;136 Suppl 1:S13-8. doi: 10.1016/j.thromres.2015.07.036.
	26354857	0	Vu TT, Leslie BA, Stafford AR, et al. Histidine-rich glycoprotein binds DNA and RNA and attenuates their capacity to activate the intrinsic coagulation pathway. Thromb Haemost. 2016 Jan;115(1):89-98. doi: 10.1160/TH15-04-0336. Epub 2015 Sep 10.
	26304938	0	Jaffer IH, Stafford AR, Fredenburgh JC, et al. Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation. J Am Heart Assoc. 2015 Aug 24;4(8):e002322. doi: 10.1161/JAHA.115.002322.
	26271200	0	van Es N, Di Nisio M, Bleker SM, et al. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost. 2015 Nov 25;114(6):1268-76. doi: 10.1160/TH15-06-0452. Epub 2015 Aug 13.
	26155974	0	Weitz JI, Pollack CV Jr. Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2015 Nov 25;114(6):1113-26. doi: 10.1160/TH15-03-0222. Epub 2015 Jul 9.
	26095746	0	Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015 Aug 6;373(6):511-20. doi: 10.1056/NEJMoa1502000. Epub 2015 Jun 22.
	26027611	0	Sarich TC, Seltzer JH, Berkowitz SD, et al. Novel oral anticoagulants and reversal agents: Considerations for clinical development. Am Heart J. 2015 Jun;169(6):751-7. doi: 10.1016/j.ahj.2015.03.010. Epub 2015 Mar 26.
	26020620	0	Pollack CV Jr, Reilly PA, Bernstein R, et al. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost. 2015 Jul;114(1):198-205. doi: 10.1160/TH15-03-0192. Epub 2015 May 28.
	25994838	0	Weitz JI, Bauersachs R, Beyer-Westendorf J, et al. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study. Thromb Haemost. 2015 Aug 31;114(3):645-50. doi: 10.1160/TH15-02-0131. Epub 2015 May 21.
	25901434	0	Buller HR, Gailani D, Weitz JI. Factor XI antisense oligonucleotide for venous thrombosis. N Engl J Med. 2015 Apr 23;372(17):1672. doi: 10.1056/NEJMc1503223.
	25879402	0	Eikelboom JW, Weitz JI. 'Realworld' use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry. Thromb Haemost. 2015 Jun;113(6):1159-61. doi: 10.1160/TH15-02-0158. Epub 2015 Apr 16.
	25792448	0	Yeh CH, Hogg K, Weitz JI. Overview of the new oral anticoagulants: opportunities and challenges. Arterioscler Thromb Vasc Biol. 2015 May;35(5):1056-65. doi: 10.1161/ATVBAHA.115.303397. Epub 2015 Mar 19.
	25789495	0	Henderson SJ, Stafford AR, Leslie BA, et al. Zinc delays clot lysis by attenuating plasminogen activation and plasmin-mediated fibrin degradation. Thromb Haemost. 2015 Jun;113(6):1278-88. doi: 10.1160/TH14-09-0771. Epub 2015 Mar 19.
	25698404	0	Weitz JI. Anticoagulation therapy in 2015: where we are and where we are going. J Thromb Thrombolysis. 2015 Apr;39(3):264-72. doi: 10.1007/s11239-015-1194-6.
	25691157	0	Vu TT, Zhou J, Leslie BA, et al. Arterial thrombosis is accelerated in mice deficient in histidine-rich glycoprotein. Blood. 2015 Apr 23;125(17):2712-9. doi: 10.1182/blood-2014-11-611319. Epub 2015 Feb 17.
	25497240	0	Cairns JA, Weitz JI. Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding. Am Heart J. 2015 Jan;169(1):1-3. doi: 10.1016/j.ahj.2014.09.007. Epub 2014 Sep 28.
	25482425	0	Buller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015 Jan 15;372(3):232-40. doi: 10.1056/NEJMoa1405760. Epub 2014 Dec 7.